Home / Healthcare / Hemophilia

Hemophilia Market By Type (Hemophilia A, Hemophilia B, Hemophilia C, Others) By Treatment (On-demand, Prophylaxis) By Therapy (Replacement therapy, ITI therapy, Gene therapy) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2028

How has the Increasing Number of Hemophilia Treatment Centers influenced the Hemophilia Market's Expansion?

Haemophilia is a genetic condition that impairs the body's capacity to form clots. A person with hemophilia is more likely to bleed for a more extended period after an injury or cut, has easy bruising, and is more likely to bleed inside joints or the brain. Hemophilia A and B are the two types of the disease. Reduced levels of clotting factor VIII characterize the former, whereas decreased levels of clotting factor IX cause the latter. Other types include parahemophilia, which is brought on by low factor V levels, and hemophilia C, which is brought on by low factor XI levels. Hemophilia affects around 1.125 million people globally. The genetic bleeding illness affects 1,125,000 men worldwide, with 418,000 suffering from a severe form of the generally undetected disease. Hemophilia was formerly considered to affect only 400,000 people worldwide.


The accessibility of limited therapeutic therapy options and the increasing pressure on regulatory authorities have resulted in increased R&D initiatives. There is a growing prevalence of hemophilia treatment centers that attempt to treat impoverished patients. Both public and commercial healthcare organizations are substantially investing in establishing specialist clinics that are set up to fulfill the specific needs of patients. The creation of healthcare centers is expected to promote the growth of the hemophilia market. Furthermore, regulatory agencies are making efforts to raise awareness about the disease and provide information about appropriate therapy.

What is the Market Size of Hemophilia in terms of Value?

The global Hemophilia Market is projected to increase at a significant CAGR of 4.70% in the coming years. In 2021, the global Hemophilia market was valued at USD 11241.4 million and projected to reach USD 14808.14 million by 2028. The demand for Hemophilia is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD 3566.74 million between 2022 and 2028.                     

Which Type of Hemophilia is the Most Common?

Hemophilia is classified as hemophilia A, hemophilia B, and others. The classification depends on the patient's coagulation factor deficit. Type A hemophilia is the most common and is four times more prevalent than type B hemophilia. According to WebMD LLC statistics published in 2019, the incidence of type A varies by country, with a spectrum of 5.4-14.5 instances per 100,000 males. Furthermore, 50-60% of patients had severe hemophilia A, which is linked to high bleeding symptoms. Furthermore, most available products are used to treat type hemophilia A.

The global Hemophilia market was valued at $11241.4 million and is expected to reach $14808.14 million by 2028.

Interesting Facts about Hemophilia Industry

  • It is anticipated that the total market will expand due to the increased prevalence of bleeding disorders and the increasing severity of those diseases due to genetic evolution. The target population, diagnosis rate, and use of preventive therapy for hemophilia are all on the rise. These factors, together with an increase in R&D studies for therapeutic solutions in the market, all help fuel its expansion.
  • The North America region dominated the hemophilia market in 2021, and this dominance is expected to continue throughout the forecast period.
  • Hemophilia therapy involves giving drugs intravenously or nasally to stop internal bleeding that frequently occurs and could lead to infection, arthritis, or joint degeneration. 
  • The government invests more funds in R&D projects, healthcare, and establishing established manufacturers. Rising target patient populations and consumer awareness of technologically advanced products also help the company's bottom line.

Who are the Top 10 Players/Companies in the Hemophilia market regarding Value?

The major firms in the global hemophilia market value Shire (Baxalta); CSL Behring; Pfizer, Inc.; Genzyme Corporation; Chugai Pharmaceutical Co. Ltd.; Bayer AG; BioMarin, Spark Therapeutics, Inc.; Novo Nordisk A/S.; and Octapharma AG. These essential players are focusing on new product launches as well as technological innovation to increase their hemophilia treatment production and obtain a competitive market share on a global scale. For instance, in 2021, BioMarin Pharmaceutical Inc. announced strong Phase 3 gene therapy study results in adults with severe hemophilia A in the United States. Over the projection period, such continuous R&D initiatives are expected to boost market demand. As a result, the variables described above are expected to boost product acceptance in the country. On the other hand, in December 2020, Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicine firm, announced improved follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, experimental gene therapy for patients with moderate to severe hemophilia A.

Who are the Top 10 Countries in the Hemophilia Market?

The major countries in the global hemophilia market are the US, Canada, Brazil, China, Japan, Australia, India, Indonesia, Malaysia, and the U.K. The frequency of hemophilia varies significantly across the United States. The estimated prevalence of hemophilia A in the United States is 12 cases per 100,000 males and 3.7 cases per 100,000 males for hemophilia B. The primary driver of regional expansion is rising prevalence and a growing preference for preventive treatment. In the United States, this condition is diagnosed at a young age. Furthermore, the government intends to launch early neonatal screening campaigns and other supportive initiatives, increasing demand for hemophilia diagnostic technologies in the United States.

Which is the Key Therapy Segment in the Hemophilia Market?

Replacement treatment is expected to be the largest sector, with gene therapy expected to become the fastest-growing category over the projection period. Replacement therapy is the standard Therapy utilized in the treatments and helps patients replenish lost clotting factors. One of the developing fields is gene therapy, particularly in finding faulty DNA bases and replacing them with functioning ones. AMT-060 is a possible therapeutic developed by UniQure for managing type B diabetes that is now in clinical studies. The Therapy works by introducing a functioning copy of the factor IX gene into liver cells of type B patients to restore factor IX production.

What are the Major Driving Factors for Hemophilia Market?

The rising prevalence of bleeding diseases and their increasing severity due to genetic evolution are expected to boost overall market expansion. The increase in R&D studies for treatment treatments in the segment and the rise in the target population, diagnosis rate, and use of preventive Therapy for hemophilia all contribute to the expansion of the hemophilia treatment market. Conversely, the increased knowledge of hemophilia in emerging nations presents a chance for the hemophilia treatment business to flourish. Rising government awareness campaigns and supported actions are planned to begin early neonatal screening, likely increasing the demand for hemophilia diagnostic equipment. An increase in the prevalence of hemophilia in newborns also drives the growth of the hemophilia market.

What are the Major Restraints for Hemophilia Market?

The high cost of hemophilia therapy, a lack of hemophilia drugs, and significant adverse effects associated with plasma-derived products are projected to limit market expansion. Hemophilia treatment is associated with significant direct expenditures such as hospitalization and pharmacological treatments and substantial indirect costs such as decreased work productivity. The inadequate knowledge in developing and underdeveloped regions restricts market expansion. The market's growth is hampered by low acceptance rates of technologically sophisticated items.

Which Region Dominated the World Hemophilia Market?

In 2021, North America will dominate the hemophilia market over the forecast period. The primary drivers of this increase are expected to be high prevalence and a growing propensity toward preventive treatment. According to the World Federation of Hospitals' annual global survey, approximately 64% of patients in the United States have chosen prophylactic treatment. In the United States, this condition is diagnosed at a young age. The region's rapid expansion can be attributed to a number of factors, including increased government investment in healthcare and R&D activities, as well as the presence of established industries. Rising awareness of technologically advanced items and an expanding target patient pool are also adding to the company's income.

Due to an increase in hemophilia patients, the Asia-Pacific region is anticipated to grow significantly. Furthermore, rising healthcare costs present a potential prospect for industry expansion. Early disease diagnosis in nations like Japan, India, Indonesia, and Malaysia, as well as increased per capita use of medications for factor VIII and IX insufficiency, are the primary impact delivery drivers. Rising healthcare infrastructure in the region's growing nations and growth in per capita income are some drivers that will propel the APAC region throughout the forecasted period. Though therapy is costly, with rising disposable income in APAC growing economies such as India and China, people should be able to afford it in the forecasted period.

Segmentation of Global Hemophilia Market-

Global Hemophilia Market – By Type 

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

Global Hemophilia Market – By Treatment 

  • On-demand
  • Prophylaxis

Global Hemophilia Market – By Therapy 

  • Replacement therapy
  • ITI therapy
  • Gene therapy

Frequently asked questions about the global Hemophilia industry

The global Hemophilia market is expected to be impacted significantly by COVID-19.

North America accounted for the highest share in the global Hemophilia market in terms of Value.

The increasing prevalence and severity of bleeding illnesses due to genetic evolution are predicted to drive overall market growth. The increase in R&D studies for treatment treatments in the segment, as well as the increase in the target population, diagnosis rate, and use of hemophilia preventive therapy, all contribute to the expansion of the hemophilia treatment market.

Hemophilia A segment had a significant share in 2021 with more than 40% of the market revenue share.

The prophylaxis segment had a significant share in 2021, with more than 60% of the market revenue share.

Hemophilia Market Scope

Report Attribute Details
Market Value in 2021 USD 11241.4 million
Market Value in 2028 USD 14808.14 million
CAGR 4.70%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Published Date:  Aug 2022
Category:  Healthcare
Report ID:   60596
Report Format:   PDF
Pages:   190
Rating:    4.7 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support